Table 5. Eight phenotypes of the better-than-expected efficacy group.
| Phenotype | Statin | Age group | Patient condition | Proportion (N) |
|
|---|---|---|---|---|---|
| Abnormal test result | Drug | ||||
| 2 | Rosuvastatin (10 mg) [96.1%] | middle-aged women [98.3%] | AST [13.7%] | Thyroxine [2.6%] | [10.60%] (237) |
| HDL 40∼59 mg/dl [13.6%] | |||||
| TC ≥240 mg/dl [13.4%] | |||||
| TC 200∼239 mg/dl (borderline high) [8.6%] | |||||
| LDL 130∼159 mg/dl (borderline high) [8.5%] | |||||
| HbA1C ≥6.5% (diabetes) [7.8%] | |||||
| 3 | Rosuvastatin (10 mg) [100.0%] | elderly women [100.0%] | HDL 40∼59 mg/dl [16.6%] | Thyroxine [2.0%] Bisphosphonate [1.2%] | [7.34%] (164) |
| AST [12.6%] | |||||
| TC 200∼239 mg/dl (borderline high) [12.1%] | |||||
| LDL 130∼159 mg/dl (borderline high) [11.6%] | |||||
| HbA1C ≥6.5% (diabetes) [11.5%] | |||||
| Glucose ≥126 mg/dl (diabetes) [9.8%] | |||||
| 5 | Rosuvastatin (10 mg) [100.0%] | middle-aged men [100.0%] | Glucose ≥126 mg/dl (diabetes) [15.8%] | Fenofibrate [1.3%] | [6.22%] (139) |
| HbA1C ≥6.5% (diabetes) [15.8%] | |||||
| TC 200∼239 mg/dl (borderline high) [13.6%] | |||||
| AST [12.5%] | |||||
| LDL 130∼159 mg/dl (borderline high) [12.1%] | |||||
| HDL 40∼59 mg/dl [11.8%] | |||||
| 6 | Rosuvastatin (10 mg) [92.5%] | elderly men [90.2%] | AST [13.4%] | Fenofibrate [1.0%] | [6.44%] (144) |
| HbA1C ≥6.5% (diabetes) [11.9%] | |||||
| HDL 40∼59 mg/dl [10.8%] | |||||
| Glucose ≥126 mg/dl (diabetes) [10.3%] | |||||
| LDL 100∼129 mg/dl (near optimal) [9.8%] | |||||
| TC 200∼239 mg/dl (borderline high) [9.6%] | |||||
| 11 | Rosuvastatin (10 mg) [100.0%] | middle-aged men [100.0%] | TC ≥240 mg/dl [20.2%] | Thyroxine [2.9%] | [3.18%] (71) |
| HDL 40∼59 mg/dl [16.8%] | |||||
| Glucose 100∼125 mg/dl (prediabetes) [15.9%] | |||||
| LDL 160∼189 mg/dl (borderline high) [14.3%] | |||||
| AST [13.9%] | |||||
| HbA1C 6∼6.4% (prediabetes) [8.1%] | |||||
| 13 | Atorvastatin (20 mg) [53.3%] Simvastatin (20 mg) [37.3%] | elderly women [100.0%] | AST [13.3%] | Bisphosphonate [1.3%] | [2.73%] (61) |
| Glucose ≥126 mg/dl (diabetes) [12.0%] | |||||
| HbA1C ≥6.5% (diabetes) [11.1%] | |||||
| HDL 40∼59 mg/dl [10.2%] | |||||
| TC 200∼239 mg/dl (borderline high) [10.2%] | |||||
| LDL 130∼159 mg/dl (borderline high) [9.3%] | |||||
| 15 | Atorvastatin (20 mg) [54.4%] Rosuvastatin (5 mg) [45.6%] | middle-aged women [100.0%] | HDL 40∼59 mg/dl [14.7%] | Thyroxine [1.4%] | [2.37%] (53) |
| AST [12.0%] | |||||
| HbA1C ≥6.5% (diabetes) [9.7%] | |||||
| Glucose ≥126 mg/dl (diabetes) [9.2%] | |||||
| TC 200∼239 mg/dl (borderline high) [9.2%] | |||||
| TC ≥240 mg/dl [9.2%] | |||||
| 17 | Rosuvastatin (10 mg) [68.6%] Atorvastatin (10 mg) [31.4%] | elderly women [100.0%] | TC ≥240 mg/dl [45.3%] | Bisphosphonate [1.0%] | [1.92%] (43) |
| LDL 160∼189 mg/dl (borderline high) [28.1%] | |||||
| LDL ≥190 mg/dl (very high) [11.3%] | |||||
| AST [9.3%] | |||||
| Glucose 100∼125 mg/dl (prediabetes) [5.0%] | |||||
| Others | [59.19%] (1323) |
||||
N = the number of patients.